Individualized Assessment of Exercise Capacity in Response to Acute and Long-Term Enzyme Replacement Therapy in Pediatric Pompe Disease.

6 min walking test (6MWT) cardiopulmonary exercise testing (CPET) enzyme replacement therapy (ERT) infantile-onset Pompe disease (IOPD) oxygen uptake at the peak of exercise (peak VO2)

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
28 Oct 2021
Historique:
received: 27 08 2021
revised: 11 10 2021
accepted: 22 10 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

Enzyme replacement therapy (ERT) with alglucosidase alfa improves the prospect of patients with infantile-onset Pompe disease (IOPD). However, a progressive decline has been reported. Objective quantification of the response to ERT when assessing newer strategies is warranted. This combined retrospective-prospective study assessed the acute and long-term effects of ERT on exercise in IOPD patients. Evaluation included cardiopulmonary exercise testing (CPET), 6-min walking test (6MWT), spirometry, motor function test (GMFM-88) and enzyme blood levels. Thirty-four CPETs (17 pre- and 17 two days-post ERT) over variable follow-up periods were performed in four patients. Two days following ERT, blood enzyme levels increased (median, 1.22 and 10.15 μmol/L/h ( The peak VO

Sections du résumé

BACKGROUND BACKGROUND
Enzyme replacement therapy (ERT) with alglucosidase alfa improves the prospect of patients with infantile-onset Pompe disease (IOPD). However, a progressive decline has been reported. Objective quantification of the response to ERT when assessing newer strategies is warranted.
METHODS METHODS
This combined retrospective-prospective study assessed the acute and long-term effects of ERT on exercise in IOPD patients. Evaluation included cardiopulmonary exercise testing (CPET), 6-min walking test (6MWT), spirometry, motor function test (GMFM-88) and enzyme blood levels.
RESULTS RESULTS
Thirty-four CPETs (17 pre- and 17 two days-post ERT) over variable follow-up periods were performed in four patients. Two days following ERT, blood enzyme levels increased (median, 1.22 and 10.15 μmol/L/h (
CONCLUSIONS CONCLUSIONS
The peak VO

Identifiants

pubmed: 34834457
pii: jpm11111105
doi: 10.3390/jpm11111105
pmc: PMC8625342
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Sanofi Genzyme
ID : Investigator's initiated grant

Références

J Pediatr. 2004 May;144(5 Suppl):S35-43
pubmed: 15126982
Phys Ther. 2009 Apr;89(4):342-50
pubmed: 19220999
J Inherit Metab Dis. 2016 May;39(3):383-390
pubmed: 26768149
Genet Med. 2021 Apr;23(4):758-766
pubmed: 33281187
Am J Respir Crit Care Med. 2003 May 15;167(10):1451; author reply 1451
pubmed: 12738602
Med Sci Sports Exerc. 2008 Feb;40(2):282-7
pubmed: 18202574
Med Sci Sports Exerc. 2012 May;44(5):771-5
pubmed: 22033515
Orphanet J Rare Dis. 2013 Jun 20;8:90
pubmed: 23787031
Muscle Nerve. 2012 Jun;45(6):831-4
pubmed: 22581536
Pediatr Pulmonol. 1995 Feb;19(2):135-42
pubmed: 7659469
Pediatr Pulmonol. 2020 Mar;55(3):674-681
pubmed: 31899940
PLoS One. 2013 Dec 31;8(12):e84120
pubmed: 24391899
PLoS One. 2013 Jun 25;8(6):e67052
pubmed: 23825616
Neuromuscul Disord. 2012 Dec;22 Suppl 3:S230-4
pubmed: 23182645
Neuromuscul Disord. 2017 Jun;27(6):542-549
pubmed: 28433478
J Pediatr. 2020 Jan;216:44-50.e5
pubmed: 31606152
Mol Genet Metab. 2010 Jan;99(1):26-33
pubmed: 19775921
Orphanet J Rare Dis. 2020 Sep 3;15(1):232
pubmed: 32883321
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
N Engl J Med. 2010 Apr 15;362(15):1396-406
pubmed: 20393176
Ann Transl Med. 2019 Jul;7(13):291
pubmed: 31392203
Neuromuscul Disord. 2015 Apr;25(4):321-32
pubmed: 25617983
Neurology. 2007 Jan 9;68(2):99-109
pubmed: 17151339
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Pediatr Pulmonol. 2018 Mar;53(3):366-373
pubmed: 29356433
Respir Care. 2014 Sep;59(9):1369-75
pubmed: 24987154
Mol Genet Metab Rep. 2020 Apr 29;23:100591
pubmed: 32373469
Res Q Exerc Sport. 2010 Dec;81(4):466-71
pubmed: 21268470
Arq Bras Cardiol. 2011 Aug;97(2):136-40
pubmed: 21739069
Lancet. 2008 Oct 11;372(9646):1342-53
pubmed: 18929906
Neurology. 2017 Dec 5;89(23):2365-2373
pubmed: 29117951
Neuromuscul Disord. 2015 Jul;25(7):542-7
pubmed: 25908581

Auteurs

Ronen Bar-Yoseph (R)

Ruth Children's Hospital, Pediatric Pulmonary Institute, Technion Faculty of Medicine, Haifa 3109601, Israel.

Galit Tal (G)

Metabolic Unit, Ruth Children's Hospital, Technion Faculty of Medicine, Haifa 3109601, Israel.

Elena Dumin (E)

Metabolic Laboratory Unit, Rambam Health Care Campus, Haifa 3109601, Israel.

Moneera Hanna (M)

Ruth Children's Hospital, Pediatric Pulmonary Institute, Haifa 3109601, Israel.

Gur Mainzer (G)

Pediatric Cardiology, Baruch Padeh Medical Center, Poriya 1528001, Israel.

Merav Zucker-Toledano (M)

Ruth Children's Hospital, Pediatric Cardiology Institute, Haifa 3109601, Israel.

George Shallufi (G)

Ruth Children's Hospital, Pediatric Pulmonary Institute, Haifa 3109601, Israel.

Mira Jahshan (M)

Technion Faculty of Medicine, Haifa 3109601, Israel.

Hanna Mandel (H)

Technion Faculty of Medicine, Haifa 3109601, Israel.
Department of Genetics and Metabolic Disorders, Ziv Medical Center, Safed 13100, Israel.

Lea Bentur (L)

Technion Faculty of Medicine, Haifa 3109601, Israel.
Children's Hospital, Rambam Health Care Center, Pediatric Pulmonary Institute, Haifa 3109601, Israel.

Classifications MeSH